Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine

• Status: Not yet recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective randomized case-control study. Six hundred patients who were firstly diagnosed as Helicobacter pylori infection will be selected, and then randomly assigned into case group and control group. Patients in control group take bismuth quadruplicate for 14 days. Patients in case group take Ban xia xie xin Decoction and bismuth agent quadruple for 14 days. Exhalation test or stool Helicobacter pylori antigen detection were used to assess the eradication rate of Helicobacter pylori 30 days (the 45th day) after treatment; Adverse reactions were evaluated on the first day (15th day) and the 30th day (45th day) after treatment. The eradication rate of Helicobacter pylori and the adverse drug reactions during the medication will be evaluated. The effect of Ban xia xie xin Decoction and bismuth quadruple based on furazolidone on the eradication of helicobacter pylori infection will be explored.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liaocheng People's Hospital
• Treatments: Bismuth

Criteria

Inclusion Criteria:

1. H. Pylori infection: Carbon13/Carbon14-urea breath test positive or rapid urease test positive or gastric mucosal tissue pathological section positive immunohistochemistry staining or gastric mucosal tissue positive H. pylori culture or fecal Positive detection of H. pylori antigen.

2. No history of H. Pylori infection eradication therapy;

3. Age 18-70 years

4. H.Pylori infection check was completed within 1 month before the start of the study.

Exclusion Criteria:

1. Pregnant or lactating women;

2. There are other serious diseases that affect the evaluation of this study, such as severe coronary heart disease, liver disease, kidney disease, chronic obstructive pulmonary disease, malignant tumor, and psychosocial diseases;

3. History of major or complex gastrointestinal surgery;

4. Those who are allergic to the drugs used in this study;

5. Patients participate other drug studies within 3 months;

6. Patients can not cooperate with the experimenter.